Speech biomarkers offer new lease of life to patient experience and trial retention
According to Adalyon’s CEO, Ulrik Zeuthen, speech-based biomarkers can be used across several applications to optimise trial operations and improve patient satisfaction.


Patient-centric approaches thrive on wearables and remote access in trials
Pharma’s AI prospects get nudged into the future with EU’s AI act
Are regulators keeping pace with AI adoption in clinical trials?
AI-automated IVF procedures represent a new era in fertility treatment